
Alligator Bioscience Q3 2023 - Awaiting the OPTIMIZE-1 Results

Redeye comments on Alligator's Q3 report. The OPTIMIZE-1 topline readout will be a major catalyst and is expected in early Q1 2024. The costs were lower and cash flow better in Q3 than in Q2, leaving the company with a cash and cash equivalents position of SEK124m.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Alligator Bioscience Q3 2023 - Awaiting the OPTIMIZE-1 Results